Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 3/2006

01-06-2006 | ORIGINAL ARTICLE

Management of sentinel lymph nodes in malignant skin tumors using dynamic lymphoscintigraphy and the single-photon-emission computed tomography/computed tomography combined system

Authors: Tsuyoshi Ishihara, Atsushi Kaguchi, Shigeto Matsushita, Shinya Shiraishi, Seiji Tomiguchi, Yasuyuki Yamashita, Toshiro Kageshita, Tomomichi Ono

Published in: International Journal of Clinical Oncology | Issue 3/2006

Login to get access
Metadata
Title
Management of sentinel lymph nodes in malignant skin tumors using dynamic lymphoscintigraphy and the single-photon-emission computed tomography/computed tomography combined system
Authors
Tsuyoshi Ishihara
Atsushi Kaguchi
Shigeto Matsushita
Shinya Shiraishi
Seiji Tomiguchi
Yasuyuki Yamashita
Toshiro Kageshita
Tomomichi Ono
Publication date
01-06-2006
Publisher
Springer-Verlag
Published in
International Journal of Clinical Oncology / Issue 3/2006
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-005-0554-1

Other articles of this Issue 3/2006

International Journal of Clinical Oncology 3/2006 Go to the issue

REVIEW ARTICLE

Methodological aspects of current problems in target-based anticancer drug development

CASE REPORT

Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib

ORIGINAL ARTICLE

Malignant change secondary to fibrous dysplasia

REVIEW ARTICLE

Treatment of chronic myeloid leukemia with imatinib mesylate

EDITORIAL

Is paclitaxel/carboplatin really a useful regimen for ovarian cancer compared with platinum/doxorubicin/cyclophosphamide?

ORIGINAL ARTICLE

Primary chemotherapy-associated effect of second-line chemotherapy on survival of patients with advanced ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits